Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Exact Sciences (EXAS) PT Raised to $20 at Jefferies
July 27, 2016 8:38 AM EDTJefferies analyst Brandon Couillard reiterated a Buy rating and raised his price target on Exact Sciences (NASDAQ: EXAS) to $20.00 (from $13.00) following strong Q2 results.
Couillard commented, "EXAS delivered an exceptionally strong 2Q that exhibited positive progress on essentially every key... More
Exact Sciences (EXAS) Tops Q2 EPS by 9c
July 26, 2016 6:20 AM EDTExact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.46), $0.09 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $18.54 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
... More